

CLAIMS

We Claim:

1. A method of treatment of a host with a cellular proliferative disease, comprising contacting said host with a colchicine family member and an antiproliferative agent, each in an amount sufficient to modulate said cellular proliferative disease.
2. The method according to claim 1, wherein said colchicine family member comprises colchicine, (S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide.
3. The method according to claim 1, wherein said colchicine family member comprises a colchicine analog.
4. The method according to claim 3 wherein said colchicine analog is thiocolchicoside, 2-demethoxy-2-glucosidoxythiocolchicine.
5. The method according to claim 1 wherein said antiproliferative agent comprises an agent that interacts with nucleic acids.
6. The method according to claim 1 wherein said antiproliferative agent comprises an agent that interacts with tubulin targets.
7. The method according to claim 6 wherein said antiproliferative agent comprises taxanes, vinca alkaloids or a tubulin targeted agent.
8. The method according to claim 1 wherein said antiproliferative agent comprises paclitaxel.
9. The method according to claim 1 wherein said antiproliferative agent comprises vinblastine.

10. The method of claim 1 wherein said antiproliferative agent comprises alkylating agents, intercalating agents, metal coordination complexes, pyrimidine nucleosides, purine nucleosides, inhibitors of nucleic acid associated enzymes, or inhibitors of nucleic acid associated proteins.

5 11. The method of claim 1 wherein said antiproliferative agent comprises etoposide.

12. The method of claim 1 wherein said antiproliferative agent comprises camptothecin.

13. The method according to claim 1 wherein said antiproliferative agent comprises cisplatin.

14. A method according to claim 1 when said colchicine family member is administered before the administration of said antiproliferative agent.

15. A method according to claim 1 when said colchicine family member is administered during the administration of said antiproliferative agent.

16. A method according to claim 1 when said colchicine family member is administered after the administration of said antiproliferative agent.

15 17. The method of claim 1 wherein the effect on said disease with said composition is greater than that for said antiproliferative agent alone.

18. A composition comprising a colchicine family member and an antiproliferative agent.

19. The composition of claim 18 wherein said colchicine family member comprises: colchicine, (S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide.

20. The composition of claim 18 wherein said colchicine family member comprises a colchicine analog.

21. The composition of claim 18 wherein said colchicine analog is thiocolchicoside, 2-demethoxy-2-glucosidoxythiocolchicine.

22. The composition of claim 18, wherein said antiproliferative agent comprises etoposide, cisplatin, or camptothecin.

5 23. The composition of claim 18, wherein said antiproliferative agent comprises vinblastine or paclitaxel.

24. Use of a colchicine family member and an antiproliferative agent in the formulation of a medicament for the treatment of a cellular proliferative disease.